source
- Teva R&D chief Eric Hughes resigns, company taps innovative medicines head as interim leadTeva announced that its chief scientific officer for research and development, Eric Hughes, M.D., Ph.D., will leave the company. Hughes, who joined Teva in 2022 as executive vice president of globa…
- Merck halts $2.7 billion BTK inhibitor program after negative phase 3 dataMerck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…